For those suffering from the lack of any really “new” news about clinical management of prostate cancer, the July issue of The ASCO Post offers some degree of relief:
- A front-page article entitled “New PSA recommendations: the debate over prostate cancer screening continues” carefully includes viewpoints from all sides this discussion, with some of the most helpful commentary coming from one of the earliest and strongest advocates for mass, population-based prostate cancer screening — Dr. David Crawford of the University of Colorado Health Sciences Center (who has now shifted his perspective considerably).
- An opinion piece by Gilbert Lawrence, MD (a radiation oncologist based in Utica, New York), and entitled “Prostate cancer management: a day late and a dollar short” offers a fierce attack on the widespread failure of the prostate cancer treatment community (regardless of specialty) to avoid over-treatment of low-risk prostate cancer.
- An extensive discussion of the data presented by Hussein et al. at the ASCO annual meeting is entitled “Continuous androgen deprivation therapy continues to be standard of care for newly diagnosed metastatic prostate cancer” (compared to intermittent ADT), but it is made very clear that this is not a point of view which is embraced by everyone who treats advanced forms of prostate cancer.
Perhaps Dr. Krongrad is right … and there really has been (almost) no new “news” in prostate cancer for the best part of 20 years. Certainly these three major issues have been with us throughout that time period!